Shukra Pharmaceuticals cash flow

Latest FY24
Cash from operations
−₹5.2cr₹3.2 cr in FY23
Capital spending
₹1.8cr−60.8% on FY23
Free cash flow
−₹7.0cr−₹1.3 cr in FY23
Cash from financing
₹12.4cr+151.1% on FY23
₹ crore except per share
Tap a line for its trendFY24Mar 2024FY23Mar 2023
Adjustments to reconcile profit — non-cash items
2.1—
0.3—
−0.6—
Changes in working capital
0.80.8
5.7−22.8
−26.226.1
Cash from operating activities
19.94.4
−4.63.4
−5.23.2
Cash from investing activities
1.84.5
0.60.1
−1.2−4.4
Cash from financing activities
0.30.3
0.10.1
12.44.9
6.03.7
10.04.0
Reference items
19.45.4
26.0%9.1%
−7.0−1.3
−9.7—
−₹8.63−₹1.64
−0.28×0.72×
0.30.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SHUKRAPHAR₹71.92

Shukra Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDPARNAXLABSGRLSUNLOCMcap ₹58 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation—2.1
+ Finance Costs—0.3
+ Interest Income—-0.6
Changes in Working Capital
+ Inventories0.80.8
+ Trade Receivables — Current-22.85.7
+ Trade Payables — Current26.1-26.2
Cash from Operating Activities
Profit Before Tax (per I/S)4.419.9
Cash from Operations (pre-tax)3.4-4.6
Cash from Operating Activities3.2-5.2
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)4.51.8
+ Interest Received — Investing0.10.6
Cash from Investing Activities-4.4-1.2
Cash from Financing Activities
+ Interest Paid0.30.3
+ Dividends Paid0.10.1
Cash from Financing Activities4.912.4
Net Changes in Cash3.76.0
Closing Cash4.010.0
Reference Items
EBITDA5.419.4
EBITDA Margin %9.1226.02
Free Cash Flow (CFO − Capex)-1.3-7.0
Free Cash Flow to Equity—-9.7
Free Cash Flow per Basic Share-1.64-8.63
Cash Flow to Net Income0.72-0.28
Cash Paid for Interest0.30.3
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.